JP2018533557A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533557A5 JP2018533557A5 JP2018517626A JP2018517626A JP2018533557A5 JP 2018533557 A5 JP2018533557 A5 JP 2018533557A5 JP 2018517626 A JP2018517626 A JP 2018517626A JP 2018517626 A JP2018517626 A JP 2018517626A JP 2018533557 A5 JP2018533557 A5 JP 2018533557A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- group
- calcitonin
- antibody
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010067003 Interleukin-33 Proteins 0.000 claims 52
- 102000017761 Interleukin-33 Human genes 0.000 claims 52
- 239000005557 antagonist Substances 0.000 claims 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 32
- 201000010099 disease Diseases 0.000 claims 16
- 208000035475 disorder Diseases 0.000 claims 16
- 230000001404 mediated effect Effects 0.000 claims 16
- 102000055006 Calcitonin Human genes 0.000 claims 15
- 108060001064 Calcitonin Proteins 0.000 claims 15
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 15
- 229960004015 calcitonin Drugs 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000000090 biomarker Substances 0.000 claims 13
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims 12
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 12
- 210000002966 serum Anatomy 0.000 claims 11
- 150000001413 amino acids Chemical group 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 102000005962 receptors Human genes 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 10
- 108010048233 Procalcitonin Proteins 0.000 claims 9
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 230000001419 dependent effect Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 claims 4
- 108090000978 Interleukin-4 Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims 2
- 101150008415 CALCA gene Proteins 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 claims 2
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims 2
- 108050003558 Interleukin-17 Proteins 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 101710191757 Resistin-like alpha Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 239000000850 decongestant Substances 0.000 claims 2
- 229940124581 decongestants Drugs 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 230000002327 eosinophilic effect Effects 0.000 claims 2
- 229960005139 epinephrine Drugs 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 102000045906 human IL33 Human genes 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 230000002992 thymic effect Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- ROMPPAWVATWIKR-UHFFFAOYSA-N 4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid Chemical compound O1C(CCCC(=O)O)=NC(C=2C=CC(Cl)=CC=2)=N1 ROMPPAWVATWIKR-UHFFFAOYSA-N 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 101150020847 CCL11 gene Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102000015833 Cystatin Human genes 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 229940122419 Interleukin 33 antagonist Drugs 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 101100022170 Mus musculus Ms4a8 gene Proteins 0.000 claims 1
- 101100533944 Mus musculus Serpina3f gene Proteins 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 102000015223 NK Cell Lectin-Like Receptors Human genes 0.000 claims 1
- 108010039435 NK Cell Lectin-Like Receptors Proteins 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 208000037884 allergic airway inflammation Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000030949 chronic idiopathic urticaria Diseases 0.000 claims 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 1
- 101150084890 cstA gene Proteins 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 108050004038 cystatin Proteins 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 230000002550 fecal effect Effects 0.000 claims 1
- 229960002462 glycopyrronium bromide Drugs 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 claims 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000002912 lymphogenic effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003551 muscarinic effect Effects 0.000 claims 1
- 208000016366 nasal cavity polyp Diseases 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 1
- 229960005330 pimecrolimus Drugs 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims 1
- 229960002586 roflumilast Drugs 0.000 claims 1
- 238000007390 skin biopsy Methods 0.000 claims 1
- 210000003594 spinal ganglia Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237624P | 2015-10-06 | 2015-10-06 | |
| US62/237,624 | 2015-10-06 | ||
| PCT/US2016/055502 WO2017062456A2 (en) | 2015-10-06 | 2016-10-05 | Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533557A JP2018533557A (ja) | 2018-11-15 |
| JP2018533557A5 true JP2018533557A5 (cg-RX-API-DMAC7.html) | 2019-11-14 |
| JP6858182B2 JP6858182B2 (ja) | 2021-04-14 |
Family
ID=57223756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517626A Active JP6858182B2 (ja) | 2015-10-06 | 2016-10-05 | インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10005834B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3359567A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6858182B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102687412B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108137682A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016333903B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3000725A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201890891A1 (cg-RX-API-DMAC7.html) |
| HK (2) | HK1259386A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA50638A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018004170A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017062456A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102400060B1 (ko) | 2013-12-26 | 2022-05-19 | 미쓰비시 타나베 파마 코퍼레이션 | 인간 항 il-33 중화 단일클론 항체 |
| SG10201805934RA (en) | 2014-01-10 | 2018-08-30 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| US20160168640A1 (en) | 2014-11-10 | 2016-06-16 | Genentech, Inc. | Therapeutic and diagnostic methods for il-33-mediated disorders |
| KR20170080604A (ko) | 2014-11-10 | 2017-07-10 | 제넨테크, 인크. | 항-인터류킨-33 항체 및 그것의 용도 |
| KR102687412B1 (ko) | 2015-10-06 | 2024-07-24 | 리제너론 파아마슈티컬스, 인크. | 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도 |
| EA037960B1 (ru) | 2016-04-27 | 2021-06-15 | Эббви Инк. | Способ лечения эозинофильного эзофагита с применением антитела против il-13 |
| SG11201808693WA (en) | 2016-04-27 | 2018-11-29 | Pfizer | Anti-il-33 antibodies, compositions, methods and uses thereof |
| CN110431240A (zh) | 2017-04-13 | 2019-11-08 | 雷杰纳荣制药公司 | 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制 |
| JP7657440B2 (ja) | 2017-06-12 | 2025-04-07 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート |
| CN115920041A (zh) * | 2017-08-31 | 2023-04-07 | 田边三菱制药株式会社 | 含有il-33拮抗剂的子宫内膜异位症治疗剂 |
| CN109061139A (zh) * | 2018-06-19 | 2018-12-21 | 温州医科大学附属第医院 | 血清炎性生物标志物在防治急性缺血性脑梗死中的应用 |
| TW202519263A (zh) * | 2019-03-21 | 2025-05-16 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
| EP4114414A4 (en) * | 2020-03-06 | 2024-03-27 | The Regents of The University of Michigan | Serine protease inhibitors for suppressing or preventing anaphylactic reaction |
| KR20220152262A (ko) | 2020-03-13 | 2022-11-15 | 제넨테크, 인크. | 항-인터루킨-33 항체 및 이의 용도 |
| JP7578943B2 (ja) * | 2020-07-13 | 2024-11-07 | 学校法人自治医科大学 | 褥瘡治療剤 |
| CN114814242B (zh) * | 2022-06-10 | 2025-04-01 | 中日友好医院(中日友好临床医学研究所) | 一种诊断慢性阻塞性肺疾病患者肌肉减少症的血液学标志物 |
| EP4658247A1 (en) * | 2023-01-31 | 2025-12-10 | Vivacelle Bio, Inc. | Compositions and methods for treating hyperprocalcitonemia |
| KR102834740B1 (ko) * | 2023-04-10 | 2025-07-17 | 아주대학교산학협력단 | Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227454C1 (de) * | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
| NZ549040A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| WO2010025393A2 (en) * | 2008-08-28 | 2010-03-04 | The Regents Of The University Of California | Protein biomarkers and methods for diagnosing kawasaki disease |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| KR20150127591A (ko) * | 2013-03-15 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | Il-33 길항제 및 이의 용도 |
| BR112016008694A2 (pt) * | 2013-10-23 | 2017-10-03 | Genentech Inc | Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit |
| KR102687412B1 (ko) | 2015-10-06 | 2024-07-24 | 리제너론 파아마슈티컬스, 인크. | 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도 |
-
2016
- 2016-10-05 KR KR1020187009724A patent/KR102687412B1/ko active Active
- 2016-10-05 WO PCT/US2016/055502 patent/WO2017062456A2/en not_active Ceased
- 2016-10-05 HK HK19101754.3A patent/HK1259386A1/zh unknown
- 2016-10-05 EP EP16790463.0A patent/EP3359567A2/en active Pending
- 2016-10-05 AU AU2016333903A patent/AU2016333903B2/en active Active
- 2016-10-05 HK HK18115046.2A patent/HK1255972A1/zh unknown
- 2016-10-05 EA EA201890891A patent/EA201890891A1/ru unknown
- 2016-10-05 US US15/285,772 patent/US10005834B2/en active Active
- 2016-10-05 CA CA3000725A patent/CA3000725A1/en active Pending
- 2016-10-05 JP JP2018517626A patent/JP6858182B2/ja active Active
- 2016-10-05 MX MX2018004170A patent/MX2018004170A/es unknown
- 2016-10-05 MA MA050638A patent/MA50638A/fr unknown
- 2016-10-05 CN CN201680058610.4A patent/CN108137682A/zh active Pending
-
2018
- 2018-05-21 US US15/985,660 patent/US10851158B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533557A5 (cg-RX-API-DMAC7.html) | ||
| JP2020513404A5 (cg-RX-API-DMAC7.html) | ||
| Fulkerson et al. | Targeting eosinophils in allergy, inflammation and beyond | |
| Izuhara et al. | IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies | |
| RU2731713C2 (ru) | Применение il-18-связывающего белка (il-18bp) при воспалительных заболеваниях | |
| JP6858182B2 (ja) | インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用 | |
| CN110167963A (zh) | 治疗发炎病况的方法 | |
| JP2016536332A5 (cg-RX-API-DMAC7.html) | ||
| ES2645368T3 (es) | Terapias para mejorar la función pulmonar | |
| RU2016134838A (ru) | Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком | |
| Grainge et al. | Targeted therapeutics for severe refractory asthma: monoclonal antibodies | |
| JP2008502366A5 (cg-RX-API-DMAC7.html) | ||
| JP2017509692A5 (cg-RX-API-DMAC7.html) | ||
| JP2013047259A (ja) | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 | |
| JP2016529232A (ja) | サイトカインアンタゴニストの標的化 | |
| RU2009120202A (ru) | Способы и композиции для лечения и мониторинга лечения связанных с il-13 расстройств | |
| EP3102601B1 (en) | Novel assay to detect human periostin | |
| KR20240049348A (ko) | 항-인터루킨-33 항체를 사용한 만성 폐쇄성 폐질환의 치료 | |
| Mitchell et al. | Anti-IgE and biologic approaches for the treatment of asthma | |
| TWI870471B (zh) | 全身性硬化症治療用醫藥組合物 | |
| CN108135913A (zh) | 治疗和/或预防特应性皮炎的il-17c拮抗剂 | |
| Syabbalo | Clinical Features and Management of Eosinophilic Asthma | |
| CN117264053B (zh) | 白介素-9的抗体及其用途 | |
| US20230091430A1 (en) | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION | |
| US20250277042A1 (en) | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF |